KalVista Pharmaceuticals (KALV) Projected to Post Quarterly Earnings on Tuesday

KalVista Pharmaceuticals (NASDAQ:KALV) will likely be releasing its Q4 2026 results before the market opens on Tuesday, March 24th. Analysts expect KalVista Pharmaceuticals to post earnings of ($0.5263) per share and revenue of $32.2860 million for the quarter. Individuals can check the company’s upcoming Q4 2026 earning summary page for the latest details on the call scheduled for Friday, March 27, 2026 at 1:00 AM ET.

KalVista Pharmaceuticals Trading Down 0.7%

Shares of KALV opened at $16.82 on Tuesday. The firm has a market cap of $850.25 million, a price-to-earnings ratio of -4.26 and a beta of -0.35. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. KalVista Pharmaceuticals has a fifty-two week low of $9.23 and a fifty-two week high of $19.00. The firm has a 50 day moving average price of $15.78 and a 200-day moving average price of $14.30.

Analyst Upgrades and Downgrades

KALV has been the subject of a number of analyst reports. HC Wainwright increased their target price on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, January 9th. Needham & Company LLC boosted their price target on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. Finally, Wall Street Zen raised KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, KalVista Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $29.40.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, insider Nicole Sweeny sold 3,975 shares of the company’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $61,890.75. Following the transaction, the insider owned 47,003 shares in the company, valued at approximately $731,836.71. This represents a 7.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Brian Piekos sold 1,767 shares of the stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $27,512.19. Following the transaction, the chief financial officer owned 13,762 shares in the company, valued at approximately $214,274.34. This trade represents a 11.38% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 33,378 shares of company stock valued at $522,290. 4.30% of the stock is owned by company insiders.

Institutional Trading of KalVista Pharmaceuticals

Several large investors have recently modified their holdings of KALV. Man Group plc purchased a new stake in shares of KalVista Pharmaceuticals during the fourth quarter worth about $282,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in KalVista Pharmaceuticals by 13.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company’s stock worth $281,000 after purchasing an additional 2,939 shares in the last quarter. Osaic Holdings Inc. purchased a new position in KalVista Pharmaceuticals in the 2nd quarter worth approximately $248,000. Sherbrooke Park Advisers LLC bought a new position in KalVista Pharmaceuticals in the 3rd quarter worth approximately $191,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC bought a new position in KalVista Pharmaceuticals in the 3rd quarter worth approximately $166,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.